Is NCT05651932 recruiting in Boston, MA?

Yes, NCT05651932 is currently recruiting participants at its Boston, MA location. This multiple myeloma clinical trial is actively enrolling qualified participants.

How do I join the multiple myeloma clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Multiple Myeloma Clinical Trial in Boston, MA

About This Multiple Myeloma Study in Boston

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

Sponsor: K36 Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

for Dose-Expansion:

≥ 18 years of age

ECOG score ≤ 1

Multiple myeloma (as per IMWG)

Prior therapy for MM: Participants must have received at least 1 and up to 3 prior lines of therapy as defined by IMWG, and the following drug classes: PI, IMiD, and anti-CD38 antibody. For mezigdomide combination Cohorts B1 and B2, participants must have received at least 2 prior lines of therapy

Participants must have a confirmed diagnosis of progressive MM (per IMWG), t(4;14) confirmed by fluorescence in situ hybridization (FISH) testing performed in a centralized Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory via fresh tumor biopsy.

Measurable disease, including at least 1 of the following criteria:

Serum M protein ≥ 0.50 g/dL (by SPEP)

Serum IgA ≥ 0.50 g/dL (IgA myeloma patients)

Urine M protein ≥ 200 mg/24 h (by UPEP)

sFLC involved light chain ≥ 10 mg/dL (100 mg/L) (patients with abnormal sFLC ratio)

Bone marrow plasma cells ≥ 30% (if only criterion for measurability)

Agreement to enroll into the REMS program (Cohort D- pomalidomide cohort only) Key

Exclusion Criteria

for Dose-Expansion:

Treatment with the following therapies in the specified time period prior to first dose:

Patients in Cohorts B1 and B2 must not have received prior mezigdomide treatment

Carfilzomib in the immediate last prior line of therapy for patients enrolled in Cohorts C1 and C2

Pomalidomide in the immediate last prior line of therapy for patients enrolled in cohort D

Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks

Cellular therapies ≤ 8 weeks

Autologous transplant \< 100 days

Allogenic transplant ≤ 6 months, or \> 6 months with active GVHD

Major surgery ≤ 4 weeks

Current plasma cell leukemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, solitary bone lesion or bone lesions as the only evidence for plasma cell dyscrasia, myelodysplastic syndrome or a myeloproliferative neoplasm or light chain amyloidosis

Active CNS disease: participants with previously treated stable CNS disease are eligible, except for Cohorts B1 and B2 for which known CNS myeloma involvement is completely excluded.

Inadequate bone marrow function

Inadequate renal, hepatic, pulmonary, and cardiac function

Active, ongoing, or uncontrolled systemic viral, bacterial, or fungal infection. Permitted prophylactic medications, antimicrobials or antiretroviral therapies defined in protocol.

Use of acid reducing agents and strong inhibitors or inducers of CYP3A4 within 7 days or 5 half-lives (whichever is longer) prior to first dose

Strong CYP1A2 inhibitors for patients receiving pomalidomide (Cohort D)

Active malignancy not related to myeloma requiring therapy within \< 2 years prior to enrollment, or not in complete remission, with exceptions defined in protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT05651932) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in Boston, MA

If you're searching for multiple myeloma treatment options in Boston, MA, this clinical trial (NCT05651932) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

Multiple Myeloma Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process